{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-005641","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.021445+00:00","generated_at":"2026-06-11T11:51:53.302356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CNS Pharma Q2 net loss $4.0M; Berubicin GBM trial enrollment at 180; topline data expected Q4 2023","bullets":["Net loss $4.0M for Q2 2023 vs $3.6M in Q2 2022; R&D expense $2.8M (up from $2.2M).","Cash $4.3M as of June 30, sufficient into Q4 2023 through interim data readout.","Berubicin GBM trial enrollment ~75% (180 of 240 patients); topline interim results expected Q4 2023.","Company reiterated upcoming milestones: enroll 200th patient in Q3, complete enrollment in Q4.","Investigation into naked short selling; believes majority of activity identified and eliminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-005641","json":"https://secwatch.observer/filing/0001683168-23-005641.json","markdown":"https://secwatch.observer/filing/0001683168-23-005641.md","text":"https://secwatch.observer/filing/0001683168-23-005641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/0001683168-23-005641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:51:53.302356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c11665813e3856d8aea57f2e467410424591b7a3","claim":"CNS Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income The net loss for the three months ended June 30, 2023 was approximately $4.0 million.","evidence_excerpt":"On August 14, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/0001683168-23-005641-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"The net loss for the three months ended June 30, 2023 was approximately $4.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}